Manufactures and sells chlortetracycline (CTC) premix and CTC hydrochloride products. Now — the numbers.
This is an established company with proven profits.
Average growth of 39% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $8.0M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 25.8× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 39% a year on average.
This stock swings about 4 times as much as the market average. Big rallies — and big drops — can both happen fast.
The price action doesn’t yet back an upward turn. Council score: 0/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.